A Phase III trial of OMS 721 for stem cell transplant-associated thrombotic microangiopathy

Trial Profile

A Phase III trial of OMS 721 for stem cell transplant-associated thrombotic microangiopathy

Planning
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs OMS 721 (Primary)
  • Indications Thrombotic microangiopathy
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top